Pfizer Inc 8-K, filed Nov 19, 2021
Pfizer Inc (PFE)
8-K
2021-11-19
For: 2021-11-15
View Original
Added on
April 10, 2026
About this 8-K
Pfizer Inc filed this 8-K on November 19, 2021, reporting on events of November 15, 2021.
Items reported
- Item 5.02: Director or officer change, or executive pay
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): November 15, 2021
(Exact name of registrant as specified in its charter)
| (State or other | (Commission File | (I.R.S. Employer | ||||||
| jurisdiction of | Number) | Identification No.) | ||||||
| incorporation) | ||||||||
| Zip code | ||||||||
(Address of principal executive offices)
Registrant’s telephone number, including area code:
(212 ) 733-2323
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Securities registered pursuant to Section 12(b) of the Act: | ||||||||||||||
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On November 17, 2021, Pfizer Inc. ("Pfizer" or the "Company") announced that Frank D'Amelio will retire from his position as Chief Financial Officer and Executive Vice President of Global Supply after nearly 15 years of distinguished service with the company. Pfizer has initiated an external search for a new Chief Financial Officer. Mr. D'Amelio will continue to serve as CFO until his successor is in place. Mr. D'Amelio made the following statement in connection with this announcement, "It’s been a privilege and a pleasure to work with Albert Bourla and my Pfizer colleagues. I remain a tremendous supporter of the Company, its leadership and direction."
Mr. D'Amelio led both the Finance and Pfizer Global Supply ("PGS") functions, having been asked by the Company to take on PGS in 2019. Having successfully completed the initial manufacturing and supply of the Pfizer-BioNTech COVID-19 vaccine, COMIRNATY, under Mr. D'Amelio’s leadership, the Company had determined that PGS will begin reporting directly to the CEO. The current leader of this function, Michael McDermott, will also become a member of the Executive Leadership Team. This organizational change is driven by the company’s desire to ensure continued high level focus and attention on all aspects of supply, manufacturing and quality.
Following the appointment of a new chief financial officer, Mr. D'Amelio will stay on as an employee advisor for a period of up to 12 months in order to ensure a smooth transition of his CFO and PGS responsibilities. Due to the impact of separating the leadership of the finance and supply functions, the Compensation Committee of the Board of Directors determined that the application of the Pfizer Executive Severance Plan was warranted and Mr. D'Amelio will be eligible to receive severance pursuant to the terms of that plan following the end of his employment.
A copy of the press release announcing Mr. D'Amelio's retirement is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. | Exhibit Description | |||||||||||||
Press Release of Pfizer Inc. dated November 17, 2021 | ||||||||||||||
| 104 | Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document. | |||||||||||||
Exhibit Index
| Exhibit No. | Exhibit Description | ||||
Press Release of Pfizer Inc. dated November 17, 2021 | |||||
| 104 | Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document. | ||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| PFIZER INC. | ||||||||
| Dated: November 19, 2021 | By: | /s/ Margaret M. Madden | ||||||
| Margaret M. Madden | ||||||||
| Senior Vice President and Corporate Secretary | ||||||||
| Chief Governance Counsel | ||||||||
Exhibit 99.1
| For Immediate Release: November 17, 2021 | Media Contact: PfizerMediaRelations@Pfizer.com +1 (212) 733-1226 | |||||||
Investor Contact: IR@Pfizer.com +1 (212) 733-4848 | ||||||||
Pfizer Announces Retirement of Chief Financial Officer
Frank D’Amelio
Mike McDermott named EVP Chief Global Supply Officer
NEW YORK, November 17, 2021 — Pfizer Inc. (NYSE: PFE) today announced that Frank D’Amelio will retire from his position as Chief Financial Officer and Executive Vice President of Global Supply at Pfizer after a nearly 15 year distinguished career with the Company. Pfizer has initiated an external search for a new Chief Financial Officer and D’Amelio has agreed to stay on board through this process and serve in a consulting role through the transition. With D’Amelio’s planned departure, and his significant contributions to Pfizer’s manufacturing capabilities, the Company has made the decision to name Mike McDermott, Executive Vice President, Chief Global Supply Officer and to have him join Pfizer’s Executive Leadership Team reporting to Chairman and Chief Executive Officer, Albert Bourla, effective January 1, 2022.
“I want to thank Frank for his many years of service to Pfizer as CFO and for the impact he has had on the Company and the patients we serve,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. “Frank has driven a strategic vision for the Company’s financial success, and he leaves Pfizer in a strong position for future growth having been instrumental in our multi-year transformation to an industry leading, science-based biopharmaceutical company.”
Frank D’Amelio joined Pfizer in 2007 and during his tenure as Chief Financial Officer the Company has generated close to $150 billion in market cap growth. He has regularly been named one of America’s top CFOs. D’Amelio led multiple acquisitions and partnerships valued at nearly $200 billion, including numerous transformative transactions such as the acquisition of Wyeth, that was essential in bringing talent and a leading vaccine platform to Pfizer, as well as the divestitures of the animal health, consumer health and mature products businesses that helped further focus the Company on scientific innovation. D’Amelio has created a world class Finance function at Pfizer and many of his team members have also become Chief Financial Officers in other companies. More recently, D’Amelio oversaw Pfizer’s manufacturing network and helped guide the organization through one of its most challenging periods as it worked to address the COVID-19 crisis.
Mike McDermott has been with Pfizer for 18 years having started with the Company in 2003 as head of then Wyeth’s Biotech Manufacturing Operations at its Pearl River, New York site. Over the years he has taken on roles with increasing levels of responsibility, and he was named President of Pfizer Global Supply in 2019. Under McDermott’s leadership, the Company was able to rapidly ramp-up production and delivery of the Pfizer-BioNTech COVID-19 vaccine, supplying more vaccines doses than any other company over the past year. As a result of his efforts, Pfizer expects to achieve the goal of producing 3 billion doses of COVID-19 vaccines in 2021 and 4 billion doses in 2022.
“Mike has been an instrumental leader in Pfizer’s global efforts to combat the SARS-CoV-2 pandemic,” said Bourla. “With our vaccine production, Mike rose to the challenge of making the impossible, possible, and I look forward to working with him more closely as we advance our new antiviral candidate and other breakthrough medicines that can impact the lives of patients around the world.”
About Pfizer: Breakthroughs That Change Patients’ Lives
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be
2
important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.
Disclosure Notice: The information contained in this release is as of November 17, 2021. The Company assumes no obligation to update forward-looking statements contained in this release as a result of new information or future events or developments.
This release contains forward-looking information about, among other things, Pfizer’s growth potential, manufacturing, distribution and supply and pipeline candidates that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development; the uncertainties inherent in business and financial planning, including, without limitation, risks related to Pfizer’s business and prospects, adverse developments in Pfizer’s markets, or adverse developments in the U.S. or global capital markets, credit markets, regulatory environment or economies generally; risks related to the availability of raw materials, manufacturing, distribution and supply; the impact of COVID-19 on our business, operations and financial results; and competitive developments.
A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.
# # #
3